BioArctic (BIOA) investor relations material

Collaboration agreement details

• Entered a research and collaboration agreement to combine BrainTransporter technology with a Lilly neurodegeneration drug candidate.

• Agreement includes a $30 million upfront payment and potential milestone payments up to $770 million.

• Eligible for tiered mid-single digit royalties on future global product sales if commercialized.

• Lilly will handle global development and commercialization of the new drug candidate.

Strategic and technological context

• BrainTransporter technology enables active drug transport across the blood-brain barrier, improving efficacy and safety.

• This is the fourth collaboration involving BrainTransporter, with BioArctic retaining rights outside these agreements.

• Technology is used in multiple in-house and external projects, with potential for future partnerships.

• BioArctic focuses on neurodegenerative diseases and has a portfolio including Alzheimer's, Parkinson's, and ALS projects.

Forward-looking statements and regulatory notes

• The agreement covers investigational uses; efficacy and safety are not yet established.

• No guarantee that the investigational agent will complete development or gain approval.